Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-08-19 00:00:00 ET · period of report 2024-08-15 · accession 0001968202-24-000122 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-08-19 | 2024-08-15 | REGN | POON CHRISTINE A | Dir | S - Sale+OE | $1,158.17 | -10.8K | 2,506 | -81% | -$12.55M |
| D | 2024-08-19 | 2024-08-15 | REGN | POON CHRISTINE A | Dir | M - OptEx | $413.33 | +10.8K | 13.0K | +499% | +$4.48M |
| D | 2024-08-19 | 2024-08-15 | REGN | POON CHRISTINE A | Dir | M - OptEx | $0.00 | -10.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-15 | S | D | 2,368 | $1,156.30 | 9,630 | D | — | — | (F2) Represents volume-weighted average price of sales of 2,368 shares of Company stock on August 15, 2024 at prices ranging from $1,156.04 to $1,156.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price. |
| 2 | Common | Common Stock | 2024-08-15 | S | D | 234 | $1,160.45 | 2,272 | D | — | — | (F6) Represents volume-weighted average price of sales of 234 shares of Company stock on August 15, 2024 at prices ranging from $1,160.10 to $1,160.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price. |
| 3 | Common | Common Stock | 2024-08-15 | M | A | 10,838 | $413.33 | 13,010 | D | — | — | |
| 4 | Common | Common Stock | 2024-08-15 | S | D | 1,012 | $1,155.72 | 11,998 | D | — | — | (F1) Represents volume-weighted average price of sales of 1,012 shares of Company stock on August 15, 2024 at prices ranging from $1,155.38 to $1,155.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price. |
| 5 | Common | Common Stock | 2024-08-15 | S | D | 100 | $1,161.32 | 2,172 | D | — | — | |
| 6 | Common | Common Stock | 2024-08-15 | S | D | 1,560 | $1,157.33 | 8,070 | D | — | — | (F3) Represents volume-weighted average price of sales of 1,560 shares of Company stock on August 15, 2024 at prices ranging from $1,157.02 to $1,157.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price. |
| 7 | Common | Common Stock | 2024-08-15 | S | D | 212 | $1,158.02 | 7,858 | D | — | — | (F4) Represents volume-weighted average price of sales of 212 shares of Company stock on August 15, 2024 at prices ranging from $1,158.01 to $1,158.08. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price. |
| 8 | Common | Common Stock | 2024-08-15 | S | D | 5,352 | $1,159.56 | 2,506 | D | — | — | (F5) Represents volume-weighted average price of sales of 5,352 shares of Company stock on August 15, 2024 at prices ranging from $1,159.18 to $1,159.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 15, 2024 at each separate price. |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-08-15 | M | D | 10,838 | $0.00 | 0 | D | $413.33 · — to 2025-01-02 | 10,838 Common Stock | (F7) The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. |